Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Trevena Inc (TRVN)

Trevena Inc (TRVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,594
  • Shares Outstanding, K 18,341
  • Annual Sales, $ 3,130 K
  • Annual Income, $ -40,290 K
  • 60-Month Beta 1.05
  • Price/Sales 1.41
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade TRVN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.68
  • Most Recent Earnings $-0.36 on 05/15/24
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -668.44%)
  • Historical Volatility 122.64%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,395.26% on 09/15/23
  • IV Low 0.00% on 07/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,130
  • Open Int (30-Day) 1,169

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +46.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1910 +28.27%
on 06/20/24
0.4200 -41.67%
on 06/18/24
-0.1475 (-37.58%)
since 06/17/24
3-Month
0.1910 +28.27%
on 06/20/24
0.4498 -45.53%
on 05/07/24
-0.1570 (-39.05%)
since 04/17/24
52-Week
0.1910 +28.27%
on 06/20/24
1.1200 -78.13%
on 09/06/23
-0.7050 (-74.21%)
since 07/17/23

Most Recent Stories

More News
Trevena: Q1 Earnings Snapshot

Trevena: Q1 Earnings Snapshot

TRVN : 0.2420 (-3.39%)
Trevena: Q4 Earnings Snapshot

Trevena: Q4 Earnings Snapshot

TRVN : 0.2420 (-3.39%)
Trevena: Q3 Earnings Snapshot

Trevena: Q3 Earnings Snapshot

TRVN : 0.2420 (-3.39%)
Trevena: Q2 Earnings Snapshot

Trevena: Q2 Earnings Snapshot

TRVN : 0.2420 (-3.39%)
Trevena: Q1 Earnings Snapshot

Trevena: Q1 Earnings Snapshot

TRVN : 0.2420 (-3.39%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.100 (unch)
SILO : 2.26 (-5.44%)
LLY : 904.04 (-3.99%)
ACOR : 0.6610 (-24.86%)
TRVN : 0.2420 (-3.39%)
IMRN : 2.69 (+0.37%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 2.26 (-5.44%)
LLY : 904.04 (-3.99%)
ACOR : 0.6610 (-24.86%)
TRVN : 0.2420 (-3.39%)
IMRN : 2.69 (+0.37%)
Trevena (NASDAQ: TRVN) Partner Receives Approval for OLINVYK in China

Trevena, Inc. (NASDAQ: TRVN) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization of

TRVN : 0.2420 (-3.39%)
Trevena: Q4 Earnings Snapshot

Trevena: Q4 Earnings Snapshot

TRVN : 0.2420 (-3.39%)
Trevena: Q3 Earnings Snapshot

Trevena: Q3 Earnings Snapshot

TRVN : 0.2420 (-3.39%)

Business Summary

Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of...

See More

Key Turning Points

3rd Resistance Point 0.2795
2nd Resistance Point 0.2676
1st Resistance Point 0.2590
Last Price 0.2420
1st Support Level 0.2385
2nd Support Level 0.2266
3rd Support Level 0.2180

See More

52-Week High 1.1200
Fibonacci 61.8% 0.7651
Fibonacci 50% 0.6555
Fibonacci 38.2% 0.5459
Last Price 0.2420
52-Week Low 0.1910

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar